4886   ASKA Pharmaceutical Holdings Co.,Ltd.

02/02/2026 15:30	Supplementary Documents of Consolidated Financial Results for the Third Quarter of FY2025
02/02/2026 15:30	Consolidated Financial Results for the Third Quarter of FY2025
12/17/2025 15:30	ASKA Achieves Score of B in Climate Change B- in Water Security and C in Forests at CDP2025
12/04/2025 11:00	ASKA Pharmaceutical Launches LEUPRORELIN ACETATE SR FOR INJECTION KIT
11/21/2025 14:00	ASKA Pharmaceutical Holdings Participates in Jefferies Global Healthcare Conference in London
11/05/2025 15:30	PPMX and ASKA Pharmaceutical Sign Joint Research Agreement to Aim to Create New Antibody Drugs
11/04/2025 16:11	Supplementary Documents for 2Q FY2025
11/04/2025 16:10	Notice of Revisions to the Forecast of Consolidated Financial Results for FY2025
11/04/2025 16:10	Consolidated Financial Results for the Second Quarter of FY2025
11/04/2025 15:30	(Correction) Partial Correction to Supplementary Documents of Consolidated Financial Results for the First Quarter of FY2025
11/04/2025 15:30	(Correction) Partial Correction to Summary of Consolidated Financial Results for the First Quarter of FY2025
10/20/2025 17:00	ASKA Obtains Marketing Authorization of Emergency Contraceptive Pill NORLEVO as Switch to OTC Use and Daiichi Sankyo Healthcare Handles Distributio
10/01/2025 11:00	ASKA Pharmaceutical Announces 20th Anniversary Initiatives
09/30/2025 18:55	Notice Regarding Termination of Procedures Based on the Response Policy to Large-scale Purchase of Company Share Certificates etc., Following the With
09/30/2025 15:30	Toray and ASKA Terminate Business Collaboration Agreement for Adhesion Barrier Agent TRM-270
09/24/2025 15:30	Personnel Change of ASKA Pharmaceutical
09/16/2025 15:30	Notice Concerning Repeated Request Made to Company Shareholders Dalton etc. for Responses to Information List Pertaining to Large-scale Purchase etc.
09/02/2025 15:30	Notice Concerning Request Made to Company Shareholders Daltone etc. for Responses to Information List Pertaining to the Large-scale Purchase etc.
08/25/2025 15:30	Notice Concerning Delivery of Information List Pertaining to the Large-scale Purchase etc. of Company Share Certificates etc
08/22/2025 15:30	Personnel Changes of ASKA Pharma Medical
08/22/2025 15:30	Personnel Changes of ASKA Pharmaceutical
08/22/2025 15:30	Personnel Changes of ASKA Pharmaceutical Holdings
08/22/2025 15:30	Personnel Changes of Corporate Officers
08/18/2025 15:30	MICIN and ASKA Enter into Agreement on Joint Development and Marketing of Irritable Bowel Syndrome Treatment App
08/18/2025 15:30	Notice Concerning Receipt of Statement of Intent for the Large-scale Purchase Actions etc. Pertaining to the Large-scale Purchase etc.
08/15/2025 15:30	ASKA Obtains Manufacturing and Marketing Approval for LEUPRORELIN ACETATE SR FOR INJECTION KIT
08/13/2025 15:30	Notice Concerning Completion of Payment for Disposal of Treasury Shares as Remuneration for Restricted Shares
08/04/2025 15:30	Supplementary Documents for 1Q FY2025
08/04/2025 15:30	Consolidated Financial Results for the First Quarter of FY2025
07/15/2025 15:30	Notice of Treasury Stock Disposal as Remuneration for Restricted Stock
07/10/2025 16:30	ASKA Pharmaceutical Holdings Included in FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index
07/01/2025 15:45	Notice Concerning Establishment of Independent Committee and Appointment of Independent Committee Members
07/01/2025 15:45	Notice Concerning Introduction of Response Policy to Large-scale Purchase etc. of Company Share Certificates etc. in Preparation for Large-scale Purch
06/30/2025 15:30	ASKA Launches Oral Contraceptive Slinda 28 Tablets in Japan
06/25/2025 15:30	ASKA to Initiate Domestic Phase III Clinical Trial of Relugolix Combination Tablet for Endometriosis
06/24/2025 15:30	Personnel Changes of ASKA Pharmaceutical Holdings Subsidiaries
06/24/2025 15:30	Personnel Changes of Board Members and Corporate Officers
06/20/2025 15:30	Personnel Change of ASKA Pharmaceutical
06/05/2025 08:00	Matters Subject to Measures for Electronic Provision of the Notice of the 4th Annual General Meeting of Shareholders
06/05/2025 08:00	NOTICE OF CONVOCATION OF THE 4th ANNUAL GENERAL MEETING OF SHAREHOLDERS
05/19/2025 15:30	ASKA Obtains Manufacturing and Marketing Approval for OralContraceptive Slinda 28 Tablets in Japan
05/12/2025 17:40	[Updated]Notice Concerning the Opinion of the Board of Directors of the Company on the Shareholder Proposal
05/12/2025 16:10	[Updated]Financial Results for FY2024
05/12/2025 15:30	Notice Concerning the Opinion of the Board of Directors of the Company on the Shareholder Proposal
05/12/2025 15:30	Supplementary Documents of Financial Results for FY2024
05/12/2025 15:30	Notice Concerning Dividends of Surplus
05/12/2025 15:30	[Summary]Consolidated Financial Results for FY2024
05/07/2025 15:30	ASKA Receives Highest Rating in DBJ Employees' Health Management Rated Loan Program by Development Bank of Japan and Financed by Same Loan
04/24/2025 15:30	Organizational and Personnel Change of ASKA Pharmaceutical Holdings
04/24/2025 15:30	Personnel Changes of Board Members and Corporate Officers
04/24/2025 15:30	Notice: Changes in Representative Directors, ASKA Pharmaceutical Holdings
04/23/2025 15:30	ASKA Announces Phase III Clinical Trial Result of TRM-270
03/12/2025 15:30	ASKA Pharmaceutical Holdings Announces Cancellation of Treasury Shares
03/10/2025 16:00	ASKA Pharmaceutical Holdings Group Recognized as White 500 Enterprise for Seventh Consecutive Year
03/10/2025 15:30	ASKA Initiates Phase I II Clinical Trial of Drospirenone Agent (LPRI-CF113) in Japan
03/03/2025 15:30	ASKA Pharmaceutical Holdings to Collaborate with MedChoice Pharma Inc through Share Acquisition of FTS Ambrose Holdings Inc.
02/21/2025 15:30	Personnel Changes of ASKA Pharmaceutical Holdings
02/21/2025 15:30	Organizational and Personnel Changes of ASKA Pharmaceutical